Drug Profile
Research programme: bFGF receptor antagonists - Praecis
Latest Information Update: 17 Jan 2008
Price :
$50
*
At a glance
- Originator Praecis Pharmaceuticals
- Class
- Mechanism of Action Fibroblast growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 16 Feb 2007 Praecis Pharmaceuticals has been acquired by GlaxoSmithKline
- 30 Aug 2002 This programme is still in active development
- 16 Aug 1999 Preclinical development for Prostate cancer in USA (Unknown route)